Download Files:
Clindamycin
$25 – $50
Products Details
Product Description
– Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].
Web ID
– HY-B1455
Storage Temperature
– -20°C (Powder, protect from light)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C18H33ClN2O5S
References
– [1]Kremsner PG. Clindamycin in malaria treatment. J Antimicrob Chemother. 1990 Jan;25(1):9-14.|[2]Hodille E, et al. Clindamycin suppresses virulence expression in inducible clindamycin-resistant Staphylococcus aureus strains. Ann Clin Microbiol Antimicrob. 2018 Oct 20;17(1):38.
CAS Number
– 18323-44-9
Molecular Weight
– 424.98
Compound Purity
– 98.49
SMILES
– CN(C[C@H](CCC)C1)[C@@H]1C(N[C@@]([C@@H](Cl)C)([H])[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)=O
Clinical Information
– Launched
Research Area
– Infection; Cancer
Solubility
– DMSO : 125 mg/mL (ultrasonic)
Target
– Antibiotic;Bacterial;Parasite
Isoform
– Plasmodium
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
